Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Table 3

Efficacy of sintilimab for recurrent or metastatic advanced esophageal cancer.

Category or variable	With radiotherapy	Without radiotherapy	value	All patients
	CR	6 (25.0)		1 (3.8)	0.031	7 (14.0)
PR	8 (33.3)	15 (57.7)		23 (46.0)
SD	8 (33.3)	8 (30.8)		16 (32.0)
PD	2 (8.3)	2 (7.7)		4 (8.0)
ORR (%)	58.3 (14/24)	61.5 (16/26)	0.817	60 (30/50)
DCR (%)	91.7 (22/24)	92.3 (24/26)	0.933	92 (46/50)

Data are number (%) or value. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate.